Artivion price target raised to $30 from $28 at Lake Street

Lake Street raised the firm’s price target on Artivion to $30 from $28 and keeps a Buy rating on the shares after the company announced it amended its purchase agreement with Endospan. The revised deal is “a win-win for Artivion and Endospan,” as it helps the deleveraging narrative and provides a clearer outlook on ROI for NEXUS, the analyst tells investors.